[go: up one dir, main page]

PE20180357A1 - Derivados de etinilo - Google Patents

Derivados de etinilo

Info

Publication number
PE20180357A1
PE20180357A1 PE2017002405A PE2017002405A PE20180357A1 PE 20180357 A1 PE20180357 A1 PE 20180357A1 PE 2017002405 A PE2017002405 A PE 2017002405A PE 2017002405 A PE2017002405 A PE 2017002405A PE 20180357 A1 PE20180357 A1 PE 20180357A1
Authority
PE
Peru
Prior art keywords
phenyl
compounds
phenyletinyl
triona
difluoro
Prior art date
Application number
PE2017002405A
Other languages
English (en)
Inventor
Georg Jaeschke
Fionn Ohara
Jean Marc Plancher
Antonio Ricci
Daniel Rueher
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20180357A1 publication Critical patent/PE20180357A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ETINILO DE FORMULA (I) DONDE R1 ES H, F O Cl; L ES UN ENLACE O ALQUILENO INFERIOR; R2 ES ALQUILO INFERIOR SUSTITUIDO CON HALOGENO, -(CH2)n-C(O)O-ALQUILO INFERIOR, ENTRE OTROS; n ES DE 1 A 3; R3 ES H, ALQUILO INFERIOR, ENTRE OTROS; R4 ES FENILO, PIRIDINILO O PIRIMIDINILO OPCIONALMENTE SUSTITUIDO POR F; Y ES CF O CCl. SON COMPUESTOS PREFERIDOS: (9aS)-7-[2,6-DIFLUORO-4-(2-FENILETINIL)FENIL]-2-(2-METOXIETIL)-9a-METIL-4,9-DIHIDRO-3H-PIRAZINO[1,2-c]PIRIMIDINA-1,6,8-TRIONA; (9aRS)-7-[2,6-DIFLUORO-4-(2-FENILETINIL)FENIL]-9a-METIL-2-(m-TOLILMETIL)-4,9-DIHIDRO-3H-PIRAZINO[1,2-c]PIRIMIDINA-1,6,8-TRIONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS POSITIVOS (MAP) DEL RECEPTOR METABOTROPICO DEL GLUTAMATO 4 (mGluR4) SIENDO UTILES PARA EL TRATAMIENTO DE LA ENFERMEDAD DEL PARKINSON, ANSIEDAD, DEPRESION, DIABETES TIPO 2
PE2017002405A 2015-08-03 2016-08-02 Derivados de etinilo PE20180357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15179550 2015-08-03

Publications (1)

Publication Number Publication Date
PE20180357A1 true PE20180357A1 (es) 2018-02-21

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002405A PE20180357A1 (es) 2015-08-03 2016-08-02 Derivados de etinilo

Country Status (20)

Country Link
US (1) US10011607B2 (es)
EP (1) EP3331882B1 (es)
JP (1) JP6975511B2 (es)
KR (1) KR20180030857A (es)
CN (1) CN107667107B (es)
AR (1) AR105556A1 (es)
AU (1) AU2016302696B2 (es)
BR (1) BR112017023951A2 (es)
CA (1) CA2983908A1 (es)
CL (1) CL2018000278A1 (es)
CO (1) CO2017011010A2 (es)
IL (1) IL255103B (es)
MX (1) MX2018001486A (es)
PE (1) PE20180357A1 (es)
PH (1) PH12018500247A1 (es)
RU (1) RU2722014C9 (es)
TW (1) TWI621619B (es)
UA (1) UA120888C2 (es)
WO (1) WO2017021384A1 (es)
ZA (1) ZA201707015B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017021879A1 (en) 2015-08-03 2017-02-09 Glenmark Pharmaceuticals S.A. Novel compounds as ror gamma modulators
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
AR105575A1 (es) 2015-08-03 2017-10-18 Bristol Myers Squibb Co COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa
CA3120053A1 (en) 2018-12-21 2020-06-25 Merck Patent Gmbh Disubstituted alkyne derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103079570A (zh) * 2009-11-06 2013-05-01 范德比尔特大学 芳基或者杂芳基砜类用作治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP5753626B2 (ja) * 2011-04-26 2015-07-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾリジン−3−オン誘導体
EA029352B1 (ru) * 2013-09-25 2018-03-30 Ф. Хоффманн-Ля Рош Аг Производные этинила
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
EP3110802B1 (en) * 2014-02-25 2018-10-10 F. Hoffmann-La Roche AG Ethynyl derivatives

Also Published As

Publication number Publication date
CN107667107A (zh) 2018-02-06
EP3331882A1 (en) 2018-06-13
ZA201707015B (en) 2018-11-28
KR20180030857A (ko) 2018-03-26
IL255103B (en) 2020-01-30
JP6975511B2 (ja) 2021-12-01
EP3331882B1 (en) 2020-04-29
UA120888C2 (uk) 2020-02-25
AU2016302696A1 (en) 2017-11-02
BR112017023951A2 (pt) 2018-07-24
CA2983908A1 (en) 2017-02-09
RU2722014C9 (ru) 2020-10-22
CN107667107B (zh) 2021-05-18
WO2017021384A1 (en) 2017-02-09
TW201718589A (zh) 2017-06-01
US10011607B2 (en) 2018-07-03
AR105556A1 (es) 2017-10-18
RU2018105872A (ru) 2019-09-05
PH12018500247A1 (en) 2018-08-13
HK1246790A1 (zh) 2018-09-14
JP2018522037A (ja) 2018-08-09
RU2722014C2 (ru) 2020-05-26
TWI621619B (zh) 2018-04-21
IL255103A0 (en) 2017-12-31
CL2018000278A1 (es) 2018-07-06
AU2016302696B2 (en) 2020-05-07
CO2017011010A2 (es) 2018-02-09
US20180127429A1 (en) 2018-05-10
MX2018001486A (es) 2018-03-15
RU2018105872A3 (es) 2019-12-26

Similar Documents

Publication Publication Date Title
CL2020000029A1 (es) Nuevos compuestos de carboxamida sulfonamida.
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20160431A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
DOP2013000181A (es) Moduladores del receptor de glucagon
MX2017006483A (es) Compuestos aminopirazina con propiedades antagonistas a2a.
JO3368B1 (ar) مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
EA201692540A1 (ru) 6,7-дигидропиразоло[1,5-a]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
PE20180357A1 (es) Derivados de etinilo
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2017016939A (es) Novedosas antagonistas 5-ht2.
PE20190609A1 (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTERICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
MX373162B (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
JO3601B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
PE20160666A1 (es) Derivados de etinilo
MX2020003185A (es) Nuevos compuestos heterociclicos.
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
UA119446C2 (uk) 1,2,4-ТРИАЗОЛО[4,3-а]ПІРИДИНОВІ СПОЛУКИ ТА ЇХ ЗАСТОСУВАННЯ ЯК ПОЗИТИВНИХ АЛОСТЕРИЧНИХ МОДУЛЯТОРІВ РЕЦЕПТОРІВ MGLUR2
PE20161415A1 (es) Derivados de etinilo